Psoriasis triggered by infliximab in a patient with Behçet's disease

Japanese Journal of Ophthalmology

Volumn 57, Issue 1, 2013, Pages 95-97

  Kawazoe, Yuko ^a   Sugita, Sunao ^a,b   Yamada, Yukiko ^a   Akino, Ai ^a   Miura, Keiko ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b RIKEN Center for Biosystems Dynamics Research   (Japan)

Author keywords

Beh et's disease; Infliximab; Psoriasis; Uveitis

Indexed keywords

COLCHICINE; HLA B51 ANTIGEN; INFLIXIMAB;

ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDERMIS HYPERPLASIA; EYE INFLAMMATION; HUMAN; HUMAN TISSUE; IRITIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; RETINA HEMORRHAGE; RETINA VASCULITIS; SKIN BIOPSY; UVEITIS; VISUAL DISORDER; VITREOUS FLOATERS; VITREOUS OPACITY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FOLLOW-UP STUDIES; HUMANS; MALE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872594499     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-012-0198-4     Document Type: Article

References (14)

1. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002;29:667-77.
2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
3. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol. 2002;46:886-91.
4. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8.
5. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404-6.
6. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet disease. Br J Opthalmol. 2010;94:284-8.
7. Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245-50.
8. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2008;16:167-71.
9. Ito T, Sonoda KH, Hijioka K, Fujimoto T, Ishibashi T. Acquired resistance to infliximab against uveitis due to Behçet's disease after one year of administration. Jpn J Ophthalmol. 2010;54:502-4.
10. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy. Arthr Rheum. 2005;52:2513-8.
11. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sörensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65:405-7.
12. Matthews C, Rogers S, FitzGerald O. Development of new-onset psoriasis while on anti-TNFalpha treatment. Ann Rheum Dis. 2006;65:1529-30.
13. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthr Rheum. 2010;40:233-40.
14. Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol. 2010;32:568-73.